Source notes

Body size and current illness are related questions, but they are not the same question. A group of 58 international experts, including people with lived experience of obesity, proposed distinguishing clinical obesity from preclinical obesity. Clinical obesity requires excess body fat together with impaired organ function or substantial limits on daily activities attributable to that excess fat. Preclinical obesity describes excess fat with preserved function, but generally increased future risk. Recommendations reached 90–100% agreement. That figure describes expert agreement, not a measured success rate for diagnosis or treatment.

The framework keeps body mass index, a weight-for-height measure, as a screening tool rather than an individual verdict on health. The authors recommend confirming excess fat with suitable additional measurements and then assessing its effects. Preclinical does not mean harmless or destined to progress. Clinical obesity also cannot be diagnosed by assuming that every symptom in a person with excess fat is caused by it.

How Does This Show Up in Real Life?

This shifts the conversation from a body-size category alone to what is happening in a person's life and organs. A useful clinical question is whether a difficulty with mobility or another daily activity reflects the effects of excess fat, and whether another cause needs to be considered. The authors recommend a medical history, examination, and appropriate tests, not a self-check based on appearance. They recommend timely, evidence-based treatment for clinical obesity and health counseling, monitoring, and risk-appropriate intervention for preclinical obesity. Their proposed treatment goals include better function and improvement in the manifestations of illness, rather than weight loss alone. Specific drug choices, procedures, and treatment indications fall outside the report's scope. It therefore informs what assessment should establish, without choosing a treatment for an individual reader.

The criteria result from evidence appraisal and expert agreement, not a prospective trial proving that this diagnostic framework improves outcomes. The authors leave a formal severity-staging system for future work. Symptoms can have other causes, making differential diagnosis essential. Agreement among experts cannot establish long-term prediction, treatment response, or persistence of benefit after treatment ends.

Why We Cite It

For Alpekin, the report offers a specific basis for avoiding blame in weight-related communication. Its attention to weight stigma can inform wording that separates a person's health needs from judgments about character or effort. This adds a communication safeguard to personalized nutrition guidance without claiming authority to diagnose disease.

This is a substantial proposal for more careful clinical assessment, not a reason to ignore weight-related risk or label people from a distance. Its practical meaning is that the purpose of care should be clear: understanding illness, protecting function, and matching support to the person's circumstances.